OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers
StockNews.AI · 9 hours
High Materiality8/10
Information
MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic data licensing agreement with
Original sourceAI Summary
OneMedNet Corporation has announced a strategic data licensing agreement with Risorius Co., Ltd., enhancing its subscription base and expected recurring revenue. This collaboration emphasizes the growing demand for real-world EEG and polysomnography data, positioning OneMedNet as a key player in the CNS research space.
Sentiment Rationale
Historical agreements in similar industries often lead to revenue growth and bolster stock performance. Such strategic partnerships can provide investors with confidence in future earnings.
Trading Thesis
Buy ONMD in anticipation of increased revenue from new licensing agreements over the next 12-18 months.
Market-Moving
- New multi-year contracts expected to significantly boost ONMD's revenue.
- Partnership with Risorius enhances OneMedNet's market positioning in CNS data services.
- Innovative applications in AI and R&D could accelerate client acquisition and retention.
Key Facts
- OneMedNet has secured a data licensing deal with Risorius.
- The agreement enhances OneMedNet's subscription contract base and recurring revenue.
- Risorius will access EEG and PSG data for R&D and AI model validation.
- The swift agreement execution highlights strong commercial alignment.
- This partnership underscores the demand for regulatory-grade neuro data.
Companies Mentioned
- Risorius Co., Ltd. (None): This partnership enhances Risorius' R&D capabilities in central nervous system applications.
Corporate Developments
This article falls under 'Corporate Developments' due to the strategic agreement enhancing OneMedNet's position in the neurotechnology field, indicating potential growth opportunities in a critical market segment.